Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Trial Profile

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Cobomarsen (Primary) ; Vorinostat
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLAR
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 07 Nov 2018 According to a miRagen Therapeutics media release, the company expects to begin dosing patients diagnosed with cutaneous T-cell lymphoma (CTCL) during the fourth quarter of 2018.
    • 07 Nov 2018 According to a miRagen Therapeutics media release, the company expect to report data from this clinical trial in the second half of 2020.
    • 22 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top